RSL Asbis

RSL REVOLUTIONARY LABS receives €700K investment from ASBIS to expand production capacity and accelerate international growth

ASBISc Enterprises Plc Invests in biotech developing novel dermaceuticals to alleviate skin side effects of cancer treatment.

LIMASSOL, CYPRUS (Nov 21, 2022) – RSL Revolutionary Labs Ltd, a healthcare-focused biotech company offering unique skincare formulations designed to treat unmet needs of oncology patients, has received a €700K investment from ASBIS Enterprises Plc.

The investment will be used to enhance the continuous efforts to develop innovative products and formulations for the needs of oncology patients. RSL Revolutionary Labs is now entering multi-centered clinical trials with new products that are based on novel collagen formulations able to heal severe medical wounds effectively. The funding will also be used to scale up production capacity in the state-of-the-art facilities housed in the brand new ASBIS Ηi-Τech Cluster to facilitate international expansion and support the needs of the local and global market.

ASBIS Enterprises Plc is a leading Value-Added Distributor, developer, and supplier of IT and IoT products, solutions, and services in the growing markets of Europe, Middle East, and Africa. ASBIS has a long-standing interest in the biotechnology and healthcare sectors and their own Perenio brand even includes a Smart Health division that is focused on innovative solutions for personal health.

“We are very excited to receive this investment as it will enable a significant upgrade of our existing capabilities, both in terms of production capacity and marketing resources to support a global expansion,” said Dr. Marianna Prokopi-Demetriades, RSL Revolutionary Lab’s Co-founder and CEO. “More importantly, this partnership will bring us even closer to the realization of our mission; to improve the quality of life of patients living with cancer by providing effective solutions that prevent further damage and promote skin healing. ASBIS as a strategic partner will fuel our vision to be at the forefront of science-based skin care management and dermal regeneration.”

Patients undergoing oncological treatment face serious dermatological issues. Available options for skin care management in cancer patients are still quite limited and products created specifically for those patients who suffer from dermatological side effects are still not widely available, are usually not effective and may contain potentially harmful chemicals.

Serhei Kostevitch, CEO of ASBIS Group, commented: “ASBIS has innovation in its DNA. We also have resources to help develop companies that can bring real value to our lives and improve its quality. That is why we are investing in another company from the biotechnology sector that develops proprietary, advanced products using the latest research on the use of collagen among others. The solutions that RSL Revolutionary Labs is working on can bring relief to millions of people around the world struggling with skin effects caused by cancer.”

About RSL Revolutionary Labs Ltd

RSL Revolutionary Labs, founded in 2019, is a healthcare-focused biotech company, offering unique skincare formulations designed in collaboration with scientists, dermatologists and oncology specialists and validated through vigorous R&D and clinical data, to address emergent needs in oncology patients. RSL provides unique natural products with the addition of novel molecularly engineered medical grade biomaterials specially formulated to alleviate skin irritation and promote wound and burn healing in cancer-associated skin conditions.


About ASBISc Enterprises Plc

ASBIS Group is a leading Value Add Distributor, developer and provider of IT, IoT products, solutions and services to the markets of Europe, the Middle East and Africa (EMEA) with local operations in Central and Eastern Europe, the Baltic republics, the former Soviet Union, the Middle East and North Africa.

The business of ASBIS is based on three pillars:

1. Distribution of hardware and software for Client Computing and Data Centers, consumer electronics thru:

a. Retail chains and e-tailers

b. Resellers to small and medium business

c. Large enterprises.

2. Full stack in creation of world class products. From scientific research and development to design and engineering, firmware and software, production and marketing of IT and IoT products and solutions via own brands:

a. Aeno (small home appliances).

b. Canyon (smart watches, power banks, accessories for computers and mobile devices)

c. Lorgar (accessories for gaming and streaming)

d. Perenio (IoT platform, IoT routers, applications and peripherals for smart office/ home, smart health).

e. Prestigio (smart devices and accessories, innovative solutions for business and education, etc.)

3. Complex solutions sales projects to large enterprises via extensive networks of System Integrators and Value Add Resellers.

ASBIS was founded in 1990 in Belarus, since 1995 operates from Cyprus. Company has two master distribution centers located in the Czech Republic and in the United Arab Emirates, subsidiaries in 27 countries, close to 2,200 employees and about, 20 000 active customers in 56 countries worldwide. In 2021, the Group delivered sales of close to USD 3.1 billion.

The Company’s stock has been listed on the Warsaw Stock Exchange since October 2007 under the ticker symbol “ASB” (ASBIS).

For more news and information visit: